SLF2 and lymphoma: To test this putative vulnerability caused by SLF2 deficiency and altered SUMOylation, we investigated the efficacy of a first‐in‐class small‐molecule inhibitor of SUMOylation (SUMOi), TAK‐981/subasumstat (Lightcap et al, 2021), which is tested in clinical phase I/II trials in lymphoma patients (NCT03648372).